Exploration of the carcinogenetic and immune role of CHK1 in human cancer.

Previous study indicated that CHK1 was important for repairing DNA damage and cell cycle regulation. To investigate the association of Checkpoint kinase 1 (CHK1) expression with clinicopathological features, prognosis, and immune infiltration in cancer. Several databases were searched for relevant publications to conduct a meta-analysis to reveal the association between CHK1 and clinicopathological features of cancer. TIMER and GEPIA datasets were utilized to explore the differential expression of CHK1 of tumors. GEPIA and Kaplan-Meier Plotter databases were adopted to detect the prognostic significance of CHK1 in tumor. TIMER and cBioPortal databases were used for the analysis regarding immune infiltration and mutation respectively. We found that CHK1 expression was significantly associated with low differentiation (OR=3.94, 95% CI: 2.73-5.67, P<0.05), advanced stage (OR=3.20, 95% CI: 2.30-4.44, P<0.05), vascular infiltration (OR=3.24, 95% CI: 2.18-4.82, P<0.05) and lymph node metastasis (OR=3.55, 95% CI: 2.62-4.82, P<0.05) of various cancers. CHK1 was highly expressed in multiple cancers and was related to clinical stage, survival, immune infiltration in pan-cancers. Our study found that CHK1 was significantly related to prognosis and immunological status in various cancers, suggesting that CHK1 may serve as a useful biomarker for prognosis and immune infiltration in cancer.